PMV appoints Matt Eckler: what the 2027 filing means for PMV Pharmaceuticals stock

Published on 10/16/2026 at 04:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

PMV plans a first-quarter 2027 filing. Matt Eckler joined the company board on October 5, 2026, a governance milestone for PMV Pharmaceuticals stock.

Clinical and financial milestones

PMV appointed Matt Eckler to its board on October 5, 2026.
Rezatapopt produced a 46.00 percent response rate among 76 evaluable patients.
PMV reported adjusted earnings per share of minus USD 0.34 for the second quarter of 2026.

PMVP, US69353Y1038, Illustration mit AI erstellt.

PMV Pharmaceuticals (ISIN US69353Y1038) appointed Matt Eckler, Ph.D., to its board on October 5, 2026, while planning a New Drug Application filing for rezatapopt in the first quarter of 2027, according to PMV Pharmaceuticals. The appointment follows completion of enrollment in the Phase 2 monotherapy portion of the PYNNACLE trial.

Three milestones frame the filing plan

PMV's recent timeline combines clinical progress with financing and governance steps. In August 2026, updated PYNNACLE data showed a 46.00 percent overall response rate among 76 evaluable patients, including four confirmed complete responses and 29 confirmed partial responses, as Yahoo Finance reported. On August 31, 2026, PMV priced an offering expected to generate USD 50.80 million in gross proceeds, the same report said.

On October 5, 2026, the board appointment became the latest milestone. The company said Eckler brings experience in healthcare investing and scientific research, while the filing plan remains tied to continued development of rezatapopt for ovarian cancer with a TP53 Y220C mutation.

What does the filing mean?

The first-quarter 2027 filing target gives the stock a concrete regulatory timetable, but the clinical evidence remains the central operating measure. The August data included a median duration of response of 10 months among patients with confirmed responses, according to Yahoo Finance. The filing depends on clinical execution and regulatory review, so the timetable is a planned milestone rather than an approval outcome.

Results date and financial base

PMV's next reported results are scheduled for November 11, 2026, according to InsiderBuying. In the second quarter of 2026, the company reported a net loss of USD 18.09 million and adjusted earnings per share of minus USD 0.34, compared with a consensus estimate of minus USD 0.40, according to Investing.com. That result places the upcoming filing plan alongside a continuing need to fund research and development.

Nasdaq listing and latest quote

PMV Pharmaceuticals is listed on the Nasdaq Global Select Market under PMVP. The latest available quote was USD 1.29 on Nasdaq on October 15, 2026 at 4:00 p.m. ET. The company is a biotechnology business focused on small molecule therapies designed to target mutant p53 proteins.